将投中网设为"星标⭐"，第一时间收获最新推送 穗城开坛，DDK到DDP的破局之道。 来源丨 投中网 9月26日，由邦勤资本与国药励展联合主办的 "从 DDK 到 DDP，医疗器械中国智造 2025" 核心技术主 题论坛在广州广交会堂圆满落幕。产业界领军者、学术界权威、医疗机构代表、金融投资专家及政企人士 齐聚一堂，围绕生物医药科技战略、器械集采优化、全球化布局、药械融合创新等关键议题深度研讨，为 中国医疗器械产业的高质量发展与全球突围建言献策。 主办方致辞 国药励展副总经理丁传军 先生 与邦勤资本总经理刘明宇博士的开场致辞，精准锚定了论坛的核心议题。 丁总表示，"DDK 到 DDP" （戴维斯双杀到戴维斯双击）的路径演进，是中国医疗器械产业从产品引 进、技术跟随走向自主创新、智能制造的缩影，这一转型不仅是产业迈向高端化的核心命题，更与 国 家"中国制造 2025" 战略形成深度呼应。在全球医疗科技加速迭代与国内健康需求升级的双重驱动 下，"掌握核心技术是竞争立足之本，实现 ' 中国智造 ' 是参与全球竞争的关键"。 刘明宇博士则从产业和资金的双重视角解读了行业转型的时代意义："DDK 到 DDP 的跨越，不仅 ...

本文源自：智通财经网 消息面上，先瑞达医疗近日公告，集团收到北京市药品监督管理局对微导丝的注册批准。微导丝适用于 常规外周血管內使用，用于引导和放置诊断或治疗用器械。公司将适时在中国开展营销活动。此外，先 瑞达医疗拟于8月26日举行董事会会议批准中期业绩。 值得注意的是，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 智通财经获悉，先瑞达医疗-B(06669)午后涨超12%，截至发稿，涨7.84%，报12.11港元，成交额 1890.18万港元。 ...

消息面上，先瑞达医疗近日公告，集团收到北京市药品监督管理局对微导丝的注册批准。微导丝适用于 常规外周血管內使用，用于引导和放置诊断或治疗用器械。公司将适时在中国开展营销活动。此外，先 瑞达医疗拟于8月26日举行董事会会议批准中期业绩。 值得注意的是，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 先瑞达医疗-B(06669)午后涨超12%，截至发稿，涨7.84%，报12.11港元，成交额1890.18万港元。 ...

智通财经APP获悉，先瑞达医疗-B(06669)午后涨超12%，截至发稿，涨7.84%，报12.11港元，成交额 1890.18万港元。 消息面上，先瑞达医疗近日公告，集团收到北京市药品监督管理局对微导丝的注册批准。微导丝适用于 常规外周血管內使用，用于引导和放置诊断或治疗用器械。公司将适时在中国开展营销活动。此外，先 瑞达医疗拟于8月26日举行董事会会议批准中期业绩。 值得注意的是，2022年12月，先瑞达医疗发布公告称，波士顿科学向公司先瑞达发起要约收购，以每股 20港元的价格交易先瑞达不超过65%股份的多数股权，预计交易金额约为5.23亿美元，完成交易后，波 科成为先瑞达医疗的控股公司。2023年7月，双方签订了合作框架协议和服务框架协议，双方将在产品 全球商业化、产品制造服务和产品研发等领域开展合作。 ...

Market Overview - The Hong Kong stock market opened slightly higher, with the Hang Seng Index rising by 0.26% to 25,241.29 points, the Hang Seng Tech Index up by 0.24% to 5,592.3 points, the National Enterprises Index increasing by 0.23% to 9,054.09 points, and the Red Chip Index gaining 0.18% to 4,373.41 points [1] Company Performance - Sinopec Oilfield Services reported revenue of approximately 37.051 billion yuan, a year-on-year increase of 0.6%, and a net profit of approximately 492 million yuan, up 9% [2] - Leap Motor achieved revenue of 24.25 billion yuan, a significant year-on-year growth of 174%, and a net profit of 30 million yuan, turning around from a loss of 2.21 billion yuan in the same period last year [2] - Wanwu Cloud reported revenue of 18.137 billion yuan, a year-on-year increase of 3.11%, and a net profit of 792 million yuan, up 3.88% [3] - China Biopharmaceuticals recorded revenue of 17.57 billion yuan, a year-on-year increase of 10.7%, and a net profit of 3.39 billion yuan, up 140.2% [3] - Tongcheng Travel reported revenue of 9.05 billion yuan, a year-on-year increase of 11.5%, with adjusted EBITDA of 2.34 billion yuan, up 35.2%, and a net profit of 1.56 billion yuan, up 28.6% [3] - Hansoh Pharmaceutical reported revenue of 7.434 billion yuan, a year-on-year increase of 14.27%, and a net profit of 3.135 billion yuan, up 15.02% [4] - Meitu reported revenue of 1.82 billion yuan, a year-on-year increase of 12.3%, and a net profit of 397 million yuan, up 30.8% [5] - Huabao International reported revenue of 1.621 billion yuan, a year-on-year increase of 2.5%, and a net profit of 118 million yuan, up 298.1% [6] - Andeli Juice reported revenue of 948 million yuan, a year-on-year increase of 50%, and a net profit of 201 million yuan, up 50.3% [6] Earnings Warnings and Surprises - Road King issued a profit warning, expecting a mid-term net loss of approximately 1.9 to 2.1 billion HKD [7] - Hui Kee Group also issued a profit warning, anticipating a mid-term net loss of approximately 800 to 900 million HKD, a year-on-year increase [8] - Yunfeng Financial issued a profit alert, expecting a mid-term net profit of approximately 480 million HKD, a significant year-on-year increase of about 139% [9] - Heung Kong Holdings issued a profit warning, expecting a mid-term net loss of 130 to 160 million HKD [10] - JS Global Life issued a profit warning, expecting a mid-term net loss of no more than 56 million USD, turning from profit to loss [11] - United Pharmaceutical issued a profit alert, expecting a mid-term net profit of approximately 1.85 billion yuan, a year-on-year increase [12] - Orange Sky Golden Harvest issued a profit alert, expecting a net profit exceeding 125 million HKD, turning from loss to profit [13] - Ximei Resources issued a profit alert, expecting a mid-term net profit of approximately 81.8 to 100 million HKD, a year-on-year increase [14] - International Resources issued a profit alert, expecting a mid-term net profit of approximately 59 million USD, a year-on-year increase [15] - Siheng Holdings issued a profit alert, expecting a mid-term net profit exceeding 50 million HKD, turning from loss to profit [16] Insurance Sector - New China Life Insurance reported cumulative original premium income of 137.806 billion yuan for the first seven months, a year-on-year increase of 23% [17] Automotive Sector - Leap Motor delivered 50,129 vehicles in July [18]

Core Viewpoint - The company, Xianruida Medical-B (06669.HK), has received registration approval from the Beijing Drug Administration for its micro-guide wire, which is intended for use in peripheral vascular procedures [1] Group 1 - The micro-guide wire is designed for guiding and placing diagnostic or therapeutic devices in routine peripheral vascular applications [1] - The company plans to initiate marketing activities in China at an appropriate time following the approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669.HK), has received registration approval from the Beijing Drug Administration for its micro-guide wire, which is designed for routine peripheral vascular use to guide and place diagnostic or therapeutic devices [1] Product Details - The micro-guide wire is available in two outer diameter specifications: 0.014 inches and 0.018 inches [1] - The product features a 10 cm soft segment at the tip with a tapered core wire design and a laser-etched wave tube, ensuring excellent delivery and torque control performance [1] - This design aims to assist physicians in addressing complex vascular challenges [1] Marketing Plans - The company plans to initiate marketing activities in China at an appropriate time following the approval [1]

Core Viewpoint - The company received registration approval for its micro-guide wire from the Beijing Drug Administration, which is designed for routine peripheral vascular use, aiding in the guidance and placement of diagnostic or therapeutic devices [1] Group 1: Product Details - The micro-guide wire is available in two outer diameter specifications: 0.014" and 0.018" [1] - The product features a soft segment at the tip measuring 10 centimeters, designed with a tapered core wire structure [1] - The outer sheath is made of laser-engraved wave tube, ensuring excellent delivery and torque control performance [1] Group 2: Market Strategy - The company plans to conduct marketing activities in China at an appropriate time following the approval [1]

Core Viewpoint - The company, Xianruida Medical-B (06669), has received registration approval from the Beijing Drug Administration for its micro-guide wire, which is designed for routine peripheral vascular use to guide and place diagnostic or therapeutic devices [1] Product Details - The micro-guide wire is available in two outer diameter specifications: 0.014 inches and 0.018 inches [1] - The product features a 10 cm soft segment at the tip with a tapered core wire design and a laser-etched wave tube, ensuring excellent delivery and torque control performance [1] Market Strategy - The company plans to conduct marketing activities in China at an appropriate time following the approval [1]